Agilent Technologies Inc (NYSE: A), a provider of analytical and clinical laboratory technology, announced on Monday that it played a key role in the FDA approval of AUCATZYL, Autolus Therapeutics' newly approved CAR T therapy.
The company's xCELLigence Real-Time Cell Analysis (RTCA) technology was instrumental in developing and validating the potency assay required for regulatory approval. By providing precise, real-time cell analysis without labels or dyes, the technology ensures accurate monitoring of cell behavior, improving reliability in drug development.
Executives from Agilent and Autolus will present insights on CAR T cell potency measurement at the 2025 Hybrid US Bioassay Conference in Tucson, Arizona, on 24-25 March 2025. The session, led by senior leaders from both companies, will highlight the role of cross-functional collaboration in advancing cell therapy development.
Agilent reported USD6.51bn in revenue for fiscal year 2024 and employs approximately 18,000 people worldwide.
Intelligent Bio Solutions strengthens IP with sixth US patent ahead of 2025 market entry
Merck's CAPVAXIVE approved by EC for pneumococcal disease prevention
Sanofi secures FDA fast track designation for chlamydia vaccine candidate
Ionis announces partnership expansion with Sobi for global olezarsen commercialisation
Nyxoah receives FDA Approvable Letter for Genio system
Palatin Technologies' PL7737 granted US FDA orphan drug designation
Benuvia Operations receives five-year contract from NIDA
Vast Therapeutics' ALX1 drug candidate granted QIDP designation by US FDA
Sanofi's tolebrutinib receives FDA priority review for multiple sclerosis treatment
GSK's Nucala (Mepolizumab) COPD application accepted by EMA
Agilent xCELLigence technology Supports FDA Approval of AUCATZYL
Journey Medical launches Emrosi for treatment of rosacea
Everest Medicines' EVM14 IND application receives US FDA approval
CStone Pharmaceuticals submits Type II variation application to EMA for sugemalimab